Is BMEA or BNTC more profitable?

Benitec Biopharma's return on equity of -34.82% beat Biomea Fusion's return on equity. Company Net Margins Return on Equity Return on Assets Biomea Fusion N/A -265.37% -103.96% Benitec Biopharma N/A -34.82% -34.11%

Which has preferable earnings and valuation, BMEA or GLSI?

Greenwich LifeSciences is trading at a lower price-to-earnings ratio than Biomea Fusion, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Biomea Fusion N/A N/A -$61.80M -$0.68 N/A Greenwich LifeSciences N/A N/A -$15.79M -$1.46 N/A

Is BMEA or GLSI more profitable?

Biomea Fusion's return on equity of -265.37% beat Greenwich LifeSciences' return on equity. Company Net Margins Return on Equity Return on Assets Biomea Fusion N/A -265.37% -103.96% Greenwich LifeSciences N/A -1,042.84% -565.43%

Does the media refer more to BMEA or GLSI?

In the previous week, Greenwich LifeSciences had 3 more articles in the media than Biomea Fusion. MarketBeat recorded 6 mentions for Greenwich LifeSciences and 3 mentions for Biomea Fusion. Biomea Fusion's average media sentiment score of 0.62 beat Greenwich LifeSciences' score of -0.07 indicating that Biomea Fusion is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Biomea Fusion 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Greenwich LifeSciences 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Does the media refer more to BMEA or ENTA?

In the previous week, Biomea Fusion had 1 more articles in the media than Enanta Pharmaceuticals. MarketBeat recorded 3 mentions for Biomea Fusion and 2 mentions for Enanta Pharmaceuticals. Enanta Pharmaceuticals' average media sentiment score of 0.76 beat Biomea Fusion's score of 0.62 indicating that Enanta Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Biomea Fusion 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Enanta Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better earnings and valuation, SNDL or BMEA?

SNDL has higher revenue and earnings than Biomea Fusion. SNDL is trading at a lower price-to-earnings ratio than Biomea Fusion, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio SNDL $677.32M 0.54 -$11.29M -$0.03 N/A Biomea Fusion N/A N/A -$61.80M -$0.68 N/A

Is SNDL or BMEA more profitable?

Biomea Fusion has a net margin of 0.00% compared to SNDL's net margin of -1.19%. SNDL's return on equity of -1.02% beat Biomea Fusion's return on equity. Company Net Margins Return on Equity Return on Assets SNDL -1.19% -1.02% -0.85% Biomea Fusion N/A -265.37% -103.96%

Does the media prefer SNDL or BMEA?

In the previous week, SNDL had 3 more articles in the media than Biomea Fusion. MarketBeat recorded 6 mentions for SNDL and 3 mentions for Biomea Fusion. SNDL's average media sentiment score of 1.06 beat Biomea Fusion's score of 0.62 indicating that SNDL is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment SNDL 0 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Biomea Fusion 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend BMEA or AVIR?

Biomea Fusion presently has a consensus price target of $8.50, indicating a potential upside of 553.85%. Given Biomea Fusion's stronger consensus rating and higher possible upside, research analysts clearly believe Biomea Fusion is more favorable than Atea Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Biomea Fusion 1 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.75 Atea Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.50

Which has stronger earnings & valuation, BMEA or AVIR?

Atea Pharmaceuticals is trading at a lower price-to-earnings ratio than Biomea Fusion, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Biomea Fusion N/A N/A -$61.80M -$0.68 N/A Atea Pharmaceuticals N/A N/A -$158.35M -$2.11 N/A

Is BMEA or AVIR more profitable?

Atea Pharmaceuticals' return on equity of -57.01% beat Biomea Fusion's return on equity. Company Net Margins Return on Equity Return on Assets Biomea Fusion N/A -265.37% -103.96% Atea Pharmaceuticals N/A -57.01% -51.49%

Does the media refer more to BMEA or AVIR?

In the previous week, Biomea Fusion and Biomea Fusion both had 3 articles in the media. Atea Pharmaceuticals' average media sentiment score of 1.04 beat Biomea Fusion's score of 0.62 indicating that Atea Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Biomea Fusion 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Atea Pharmaceuticals 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Biomea Fusion (BMEA) Competitors

$1.30 -0.07 (-5.11%)

Closing price 04:00 PM Eastern

Extended Trading

$1.34 +0.04 (+3.08%)

As of 07:15 PM Eastern

Compare

BMEA vs. BNTC, GLSI, ENTA, SNDL, and AVIR

Should you buy Biomea Fusion stock or one of its competitors? MarketBeat compares Biomea Fusion with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Biomea Fusion include Benitec Biopharma (BNTC), Greenwich LifeSciences (GLSI), Enanta Pharmaceuticals (ENTA), SNDL (SNDL), and Atea Pharmaceuticals (AVIR). These companies are all part of the "pharmaceutical products" industry.

How does Biomea Fusion compare to Benitec Biopharma?

Biomea Fusion (NASDAQ:BMEA) and Benitec Biopharma (NASDAQ:BNTC) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, earnings, media sentiment, risk, dividends and valuation.

Benitec Biopharma has higher revenue and earnings than Biomea Fusion. Benitec Biopharma is trading at a lower price-to-earnings ratio than Biomea Fusion, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biomea Fusion	N/A	N/A	-$61.80M	-$0.68	N/A
Benitec Biopharma	$80K	4,465.50	-$37.92M	-$1.14	N/A

96.7% of Biomea Fusion shares are held by institutional investors. Comparatively, 52.2% of Benitec Biopharma shares are held by institutional investors. 10.6% of Biomea Fusion shares are held by company insiders. Comparatively, 4.8% of Benitec Biopharma shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, Benitec Biopharma had 5 more articles in the media than Biomea Fusion. MarketBeat recorded 8 mentions for Benitec Biopharma and 3 mentions for Biomea Fusion. Benitec Biopharma's average media sentiment score of 0.86 beat Biomea Fusion's score of 0.62 indicating that Benitec Biopharma is being referred to more favorably in the news media.

Company	Overall Sentiment
Biomea Fusion	Positive
Benitec Biopharma	Positive

Biomea Fusion presently has a consensus price target of $8.50, suggesting a potential upside of 553.85%. Benitec Biopharma has a consensus price target of $27.00, suggesting a potential upside of 159.62%. Given Biomea Fusion's stronger consensus rating and higher possible upside, equities research analysts plainly believe Biomea Fusion is more favorable than Benitec Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biomea Fusion	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.75
Benitec Biopharma	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

Biomea Fusion has a beta of -0.31, indicating that its stock price is 131% less volatile than the broader market. Comparatively, Benitec Biopharma has a beta of 0.27, indicating that its stock price is 73% less volatile than the broader market.

Benitec Biopharma's return on equity of -34.82% beat Biomea Fusion's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biomea Fusion	N/A	-265.37%	-103.96%
Benitec Biopharma	N/A	-34.82%	-34.11%

Summary

Biomea Fusion and Benitec Biopharma tied by winning 7 of the 14 factors compared between the two stocks.

How does Biomea Fusion compare to Greenwich LifeSciences?

Biomea Fusion (NASDAQ:BMEA) and Greenwich LifeSciences (NASDAQ:GLSI) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, dividends, earnings, risk, profitability, analyst recommendations, institutional ownership and media sentiment.

In the previous week, Greenwich LifeSciences had 3 more articles in the media than Biomea Fusion. MarketBeat recorded 6 mentions for Greenwich LifeSciences and 3 mentions for Biomea Fusion. Biomea Fusion's average media sentiment score of 0.62 beat Greenwich LifeSciences' score of -0.07 indicating that Biomea Fusion is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Biomea Fusion	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Greenwich LifeSciences	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Biomea Fusion's return on equity of -265.37% beat Greenwich LifeSciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biomea Fusion	N/A	-265.37%	-103.96%
Greenwich LifeSciences	N/A	-1,042.84%	-565.43%

Greenwich LifeSciences is trading at a lower price-to-earnings ratio than Biomea Fusion, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biomea Fusion	N/A	N/A	-$61.80M	-$0.68	N/A
Greenwich LifeSciences	N/A	N/A	-$15.79M	-$1.46	N/A

Biomea Fusion has a beta of -0.31, indicating that its share price is 131% less volatile than the broader market. Comparatively, Greenwich LifeSciences has a beta of 1.4, indicating that its share price is 40% more volatile than the broader market.

Biomea Fusion currently has a consensus price target of $8.50, indicating a potential upside of 553.85%. Greenwich LifeSciences has a consensus price target of $47.50, indicating a potential upside of 95.55%. Given Biomea Fusion's stronger consensus rating and higher possible upside, analysts plainly believe Biomea Fusion is more favorable than Greenwich LifeSciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biomea Fusion	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.75
Greenwich LifeSciences	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

96.7% of Biomea Fusion shares are owned by institutional investors. Comparatively, 4.2% of Greenwich LifeSciences shares are owned by institutional investors. 10.6% of Biomea Fusion shares are owned by company insiders. Comparatively, 51.5% of Greenwich LifeSciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Biomea Fusion beats Greenwich LifeSciences on 9 of the 13 factors compared between the two stocks.

How does Biomea Fusion compare to Enanta Pharmaceuticals?

Biomea Fusion (NASDAQ:BMEA) and Enanta Pharmaceuticals (NASDAQ:ENTA) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, dividends, analyst recommendations, valuation, institutional ownership, earnings, profitability and risk.

96.7% of Biomea Fusion shares are held by institutional investors. Comparatively, 95.0% of Enanta Pharmaceuticals shares are held by institutional investors. 10.6% of Biomea Fusion shares are held by insiders. Comparatively, 11.5% of Enanta Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Biomea Fusion has higher earnings, but lower revenue than Enanta Pharmaceuticals. Enanta Pharmaceuticals is trading at a lower price-to-earnings ratio than Biomea Fusion, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biomea Fusion	N/A	N/A	-$61.80M	-$0.68	N/A
Enanta Pharmaceuticals	$65.32M	5.00	-$81.89M	-$2.59	N/A

In the previous week, Biomea Fusion had 1 more articles in the media than Enanta Pharmaceuticals. MarketBeat recorded 3 mentions for Biomea Fusion and 2 mentions for Enanta Pharmaceuticals. Enanta Pharmaceuticals' average media sentiment score of 0.76 beat Biomea Fusion's score of 0.62 indicating that Enanta Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Biomea Fusion	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Enanta Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Biomea Fusion has a net margin of 0.00% compared to Enanta Pharmaceuticals' net margin of -89.56%. Enanta Pharmaceuticals' return on equity of -64.04% beat Biomea Fusion's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biomea Fusion	N/A	-265.37%	-103.96%
Enanta Pharmaceuticals	-89.56%	-64.04%	-20.22%

Biomea Fusion currently has a consensus target price of $8.50, indicating a potential upside of 553.85%. Enanta Pharmaceuticals has a consensus target price of $20.29, indicating a potential upside of 80.48%. Given Biomea Fusion's higher possible upside, equities analysts plainly believe Biomea Fusion is more favorable than Enanta Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biomea Fusion	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.75
Enanta Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.75

Biomea Fusion has a beta of -0.31, suggesting that its share price is 131% less volatile than the broader market. Comparatively, Enanta Pharmaceuticals has a beta of 0.97, suggesting that its share price is 3% less volatile than the broader market.

Summary

Biomea Fusion beats Enanta Pharmaceuticals on 7 of the 13 factors compared between the two stocks.

How does Biomea Fusion compare to SNDL?

SNDL (NASDAQ:SNDL) and Biomea Fusion (NASDAQ:BMEA) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their media sentiment, analyst recommendations, institutional ownership, earnings, valuation, profitability, risk and dividends.

SNDL has a beta of 0.91, suggesting that its stock price is 9% less volatile than the broader market. Comparatively, Biomea Fusion has a beta of -0.31, suggesting that its stock price is 131% less volatile than the broader market.

SNDL has higher revenue and earnings than Biomea Fusion. SNDL is trading at a lower price-to-earnings ratio than Biomea Fusion, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
SNDL	$677.32M	0.54	-$11.29M	-$0.03	N/A
Biomea Fusion	N/A	N/A	-$61.80M	-$0.68	N/A

96.7% of Biomea Fusion shares are held by institutional investors. 10.6% of Biomea Fusion shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, SNDL had 3 more articles in the media than Biomea Fusion. MarketBeat recorded 6 mentions for SNDL and 3 mentions for Biomea Fusion. SNDL's average media sentiment score of 1.06 beat Biomea Fusion's score of 0.62 indicating that SNDL is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
SNDL	0 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Biomea Fusion	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Biomea Fusion has a net margin of 0.00% compared to SNDL's net margin of -1.19%. SNDL's return on equity of -1.02% beat Biomea Fusion's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
SNDL	-1.19%	-1.02%	-0.85%
Biomea Fusion	N/A	-265.37%	-103.96%

SNDL presently has a consensus price target of $5.00, suggesting a potential upside of 254.61%. Biomea Fusion has a consensus price target of $8.50, suggesting a potential upside of 553.85%. Given Biomea Fusion's stronger consensus rating and higher probable upside, analysts clearly believe Biomea Fusion is more favorable than SNDL.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
SNDL	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Biomea Fusion	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.75

Summary

SNDL beats Biomea Fusion on 8 of the 15 factors compared between the two stocks.

How does Biomea Fusion compare to Atea Pharmaceuticals?

Biomea Fusion (NASDAQ:BMEA) and Atea Pharmaceuticals (NASDAQ:AVIR) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, valuation, media sentiment, risk, earnings, analyst recommendations, dividends and institutional ownership.

Atea Pharmaceuticals' return on equity of -57.01% beat Biomea Fusion's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biomea Fusion	N/A	-265.37%	-103.96%
Atea Pharmaceuticals	N/A	-57.01%	-51.49%

Biomea Fusion has a beta of -0.31, meaning that its stock price is 131% less volatile than the broader market. Comparatively, Atea Pharmaceuticals has a beta of 0.32, meaning that its stock price is 68% less volatile than the broader market.

96.7% of Biomea Fusion shares are held by institutional investors. Comparatively, 86.7% of Atea Pharmaceuticals shares are held by institutional investors. 10.6% of Biomea Fusion shares are held by company insiders. Comparatively, 21.6% of Atea Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Biomea Fusion and Biomea Fusion both had 3 articles in the media. Atea Pharmaceuticals' average media sentiment score of 1.04 beat Biomea Fusion's score of 0.62 indicating that Atea Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Biomea Fusion	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Atea Pharmaceuticals	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Biomea Fusion presently has a consensus price target of $8.50, indicating a potential upside of 553.85%. Given Biomea Fusion's stronger consensus rating and higher possible upside, research analysts clearly believe Biomea Fusion is more favorable than Atea Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biomea Fusion	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.75
Atea Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.50

Atea Pharmaceuticals is trading at a lower price-to-earnings ratio than Biomea Fusion, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biomea Fusion	N/A	N/A	-$61.80M	-$0.68	N/A
Atea Pharmaceuticals	N/A	N/A	-$158.35M	-$2.11	N/A

Summary

Biomea Fusion beats Atea Pharmaceuticals on 7 of the 13 factors compared between the two stocks.

Get Biomea Fusion News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BMEA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BMEA vs. The Competition

Export

Metric	Biomea Fusion	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$93.99M	$3.28B	$6.45B	$12.42B
Dividend Yield	N/A	2.33%	2.69%	5.29%
P/E Ratio	-1.91	17.93	22.30	24.19
Price / Sales	N/A	324.62	581.44	138.36
Price / Cash	N/A	116.27	42.31	57.88
Price / Book	3.10	6.63	9.84	6.72
Net Income	-$61.80M	$24.20M	$3.57B	$337.19M
7 Day Performance	-4.41%	-3.24%	-1.16%	0.48%
1 Month Performance	-5.11%	0.53%	3.85%	5.07%
1 Year Performance	-47.79%	47.24%	27.40%	34.25%

Biomea Fusion Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BMEA Biomea Fusion	1.988 of 5 stars	$1.30 -5.1%	$8.50 +553.8%	-11.6%	$93.99M	N/A	N/A	50
BNTC Benitec Biopharma	2.2987 of 5 stars	$10.82 -6.4%	$27.00 +149.5%	-32.2%	$397.13M	N/A	N/A	20	Gap Down
GLSI Greenwich LifeSciences	1.516 of 5 stars	$28.51 +8.9%	$47.50 +66.6%	+152.0%	$395.01M	N/A	N/A	3	News Coverage Gap Up
ENTA Enanta Pharmaceuticals	2.2714 of 5 stars	$12.67 -3.7%	$20.29 +60.1%	+91.3%	$382.67M	$65.32M	N/A	160	Analyst Downgrade
SNDL SNDL	3.4662 of 5 stars	$1.46 -1.4%	$5.00 +242.5%	+13.4%	$380.95M	$677.32M	N/A	2,751	News Coverage Positive News Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BMEA) was last updated on 6/3/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Biomea Fusion (BMEA) Competitors

BMEA vs. BNTC, GLSI, ENTA, SNDL, and AVIR

How does Biomea Fusion compare to Benitec Biopharma?

Summary

How does Biomea Fusion compare to Greenwich LifeSciences?

Summary

How does Biomea Fusion compare to Enanta Pharmaceuticals?

Summary

How does Biomea Fusion compare to SNDL?

Summary

How does Biomea Fusion compare to Atea Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BMEA vs. The Competition

Biomea Fusion Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Biomea Fusion (BMEA) Competitors

BMEA vs. BNTC, GLSI, ENTA, SNDL, and AVIR

How does Biomea Fusion compare to Benitec Biopharma?

Which has better earnings and valuation, BMEA or BNTC?

Do institutionals & insiders have more ownership in BMEA or BNTC?

Does the media refer more to BMEA or BNTC?

Do analysts rate BMEA or BNTC?

Which has more risk & volatility, BMEA or BNTC?

Is BMEA or BNTC more profitable?

Summary

How does Biomea Fusion compare to Greenwich LifeSciences?

Does the media refer more to BMEA or GLSI?

Is BMEA or GLSI more profitable?

Which has preferable earnings and valuation, BMEA or GLSI?

Which has more risk and volatility, BMEA or GLSI?

Do analysts rate BMEA or GLSI?

Do institutionals and insiders believe in BMEA or GLSI?

Summary

How does Biomea Fusion compare to Enanta Pharmaceuticals?

Do insiders and institutionals hold more shares of BMEA or ENTA?

Which has higher valuation and earnings, BMEA or ENTA?

Does the media refer more to BMEA or ENTA?

Is BMEA or ENTA more profitable?

Do analysts prefer BMEA or ENTA?

Which has more risk & volatility, BMEA or ENTA?

Summary

How does Biomea Fusion compare to SNDL?

Which has more risk and volatility, SNDL or BMEA?

Which has better earnings and valuation, SNDL or BMEA?

Do insiders and institutionals have more ownership in SNDL or BMEA?

Does the media prefer SNDL or BMEA?

Is SNDL or BMEA more profitable?

Do analysts recommend SNDL or BMEA?

Summary

How does Biomea Fusion compare to Atea Pharmaceuticals?

Is BMEA or AVIR more profitable?

Which has more volatility and risk, BMEA or AVIR?

Do institutionals & insiders hold more shares of BMEA or AVIR?

Does the media refer more to BMEA or AVIR?

Do analysts recommend BMEA or AVIR?

Which has stronger earnings & valuation, BMEA or AVIR?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BMEA vs. The Competition

Biomea Fusion Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools